U.S. markets closed

PDL BioPharma, Inc. (PDLI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2800-0.0300 (-0.91%)
At close: 4:00PM EDT

3.2800 0.00 (0.00%)
After hours: 4:00PM EDT

PDL BioPharma, Inc.

932 Southwood Boulevard
Incline Village 89451
United States
775 832 8500
http://www.pdl.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees109

Key Executives

NameTitlePayExercisedYear Born
Mr. Dominique P. MonnetCEO, Pres & Director1.2MN/A1961
Mr. Edward A. Imbrogno CPAVP, CFO & Chief Accounting Officer564.14kN/A1965
Mr. Christopher L. StoneVP, Gen. Counsel & Sec.1.15MN/A1964
Mr. Nathan KryszakDeputy Gen. Counsel & Assistant Sec.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Medical Devices segment offers LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Strategic Positions segment develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Corporate Governance

PDL BioPharma, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.